血清学模型与Fibroscan联合诊断肝纤维化研究进展

doi:10.3969/j.issn.1672-5069.2012.05.0039

实用肝脏病杂志 ›› 2012, Vol. 15 ›› Issue (5): 472-474.doi: 10.3969/j.issn.1672-5069.2012.05.0039

血清学模型与Fibroscan联合诊断肝纤维化研究进展

李欣综述, 马红审校

100050 北京市首都医科大学附属北京友谊医院肝脏内科

收稿日期:2011-12-06 出版日期:2012-10-10 发布日期:2017-03-09
通讯作者: 马红,E-mail：mahongmd@yahoo.com.cn
作者简介:李欣女,24岁,硕士研究生

Received:2011-12-06 Online:2012-10-10 Published:2017-03-09

摘要/Abstract

摘要： 由于肝活检诊断肝纤维化的局限性,临床上需要建立肝纤维化的无创诊断模型。已知的血清学模型有Fibrotest、APRI指数、Hepascore、FIB-4和ELF等。联合检测各种血清学模型和Fibroscan检查可提高肝纤维化的诊断准确率,减少肝活检,并有助于判断肝纤维化患者的预后。

关键词: 肝纤维化, 无创诊断, 血清学模型, Fibroscan

李欣综述, 马红审校. 血清学模型与Fibroscan联合诊断肝纤维化研究进展[J]. 实用肝脏病杂志, 2012, 15(5): 472-474.

[1] Schmeltzer PA,Talwalkar JA. Noninvasive tools to assess hepatic fibrosis:ready for prime time. Gastroenterol Clin North Am,2011,40（3）:507-521.
[2] Valva P,Casciato P,Diaz carrasco JM,et al. The role of serum biomarkers in predicting fibrosis progression in pediatric and adult hepatitis C virus chronic infection.PLoS One,2011,6（8）: e23218.
[3] Ahmad W,Ijaz B,Javed FT,et al. A comparison of four fibrosis indexes in chronic HCV:Development of new fibrosis-cirrhosis index（FCI）. BMC Gastroenterol,2011,11:44.
[4] Wu SD,Wang JY,Li L. Staging of liver fibrosis in chronic hepatitis B patients with a composite predictive model:A comparative study. World J Gastroenterol,2010,16（4）:501-507.
[5] Poynard T,Ngo Y,Munteanu M,et al. Noninvasive markers of hepatic fibrosis in chronic hepatitis B. Curr Hepat Rep,2011,10:87-97.
[6] Dowman JK,Tomlinson JW,Newsome PN. Systematic review: the diagnosis and staging of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. Aliment Pharmacol Ther,2011,33:525-540.
[7] Castera L. Non-invasive assessment of liver fibrosis in chronic hepatitis C. Hepatol Int,2011,5:625-634.
[8] Trang T,Petersen JR,Snyder N. Non-invasive markers of hepatic fibrosis in patients co-infected with HCV and HIV: Comparison of the APRI and FIB-4 index. Clinica Chimica Acta,2008,397:51-54.
[9] Güzelbulut F,etinkaya ZA,Sezikli M,et al. AST-platelet ratio index,Forns index and FIB-4 in the prediction of significant fibrosis and cirrhosis in patients with chronic hepatitis C. Turk J Gastroenterol,2011,22（3）:279-285.
[10] Friedrich-rust M,Rosenberg W,Parkes J,et al. Comparison of ELF,FibroTest and FibroScan for the non-invasive assessment of liver fibrosis. BMC Gastroenterol,2010,10:103.
[11] Alkhouri N,Carter-kent C,Lopez R,et al. Combination of the pediatric NAFLD fibrosis index and enhanced liver fibrosis test identifies children with fibrosis. Clin Gastroenterol Hepatol,2011,9（2）:150-155.
[12] Bourliere M,Penaranda G,Ouzan D,et al. Optimized stepwise combination algorithms of non-invasive liver fibrosis scores including Hepascore in hepatitis C virus patients. Aliment Pharmacol Ther,2008,28:458-467.
[13] Sebastiani G,Halfon P,Castera L,et al. SAFE biopsy: a validated method for large-scale staging of liver fibrosis in chronic hepatitis C. Hepatology,2009,49:1821-1827.
[14] Van de putte DF,Blom R,Van soest H,et al. Impact of Fibroscan on management of chronic viral hepatitis in clinical practice.Ann Hepatol,2011,10（4）:469-476.
[15] Castera L,Sebastiani G,Bail BL,et al. Prospective comparison of two algorithms combining non-invasive methods for staging liver fibrosis in chronic hepatitis C. J Hepatol,2010,52:191-198.
[16] Boursier J,Ledinghen V,Zarski JP,et al. A new combination of blood test and Fibroscan for accurate non-invasive diagnosis of liver fibrosis stages in chronic hepatitis C. Am J Gastroenterol,2011,106（7）:1255-1263.
[17] Vergniol J,Foucher J,Terrebonne E,et al. Noninvasive tests for fibrosis and liver stiffness predict 5-year outcomes of patients with chronic hepatitis C. Gastroenterology,2011,140（7）:1970-1979.

血清学模型与Fibroscan联合诊断肝纤维化研究进展

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	. 肝纤维化诊断及治疗共识（2019年）[J]. 实用肝脏病杂志, 2019, 22(6): 793-803.
[2]	闵峰, 黄文琪, 吴卫兵, 张丽, 范荣华. 慢性乙型肝炎患者血清脂肪细胞因子水平变化及其临床意义^*[J]. 实用肝脏病杂志, 2019, 22(6): 824-827.
[3]	吴海义, 陈建新. 四种诊断模型诊断乙型肝炎病毒携带者肝纤维化的效能分析^*[J]. 实用肝脏病杂志, 2019, 22(6): 832-835.
[4]	陈梅梅, 段晓燕, 曹海霞, 丁雯瑾. 复方鳖甲软肝片治疗原发性胆汁性肝硬化患者疗效分析^*[J]. 实用肝脏病杂志, 2019, 22(6): 880-883.
[5]	高伟, 侯勇. 肝脏硬度值检测诊断慢性乙型肝炎患者肝组织纤维化的效能分析*[J]. 实用肝脏病杂志, 2019, 22(5): 652-655.
[6]	程华, 鞠辉, 宋德顺, 李伟. 慢性乙型肝炎患者血清血管生成素样蛋白2和高尔基体蛋白73水平变化及其诊断显著肝纤维化的效能分析^*[J]. 实用肝脏病杂志, 2019, 22(4): 494-497.
[7]	余英芳, 温生宝. 应用磁共振DWI单指数、双指数和拉伸指数模型参数评估慢性乙型肝炎患者肝纤维化程度效能研究^*[J]. 实用肝脏病杂志, 2019, 22(4): 502-505.
[8]	张亚飞, 叶珺, 谢琴秀, 邹桂舟, 李家斌, 李旭, 张振华. 不同医院无创性肝纤维化指标预测慢性乙型肝炎患者肝纤维化效能差异分析^*[J]. 实用肝脏病杂志, 2019, 22(4): 510-513.
[9]	谢晓, 刘婷, 董志霞, 夏幼辰, 张启迪, 曲颖, 蔡晓波, 徐铭益, 陆伦根. FibroTouch检测肝脏受控衰减参数对肝脂肪变的诊断价值分析^*[J]. 实用肝脏病杂志, 2019, 22(4): 526-529.
[10]	周丽云, 李校天, 李丽, 杨俊超. 1,25（OH）₂D₃通过调节miR-146a水平抑制大鼠肝纤维化的体内和体外观察[J]. 实用肝脏病杂志, 2019, 22(3): 333-336.
[11]	吴亚平,周冰清,蒋蓓莉. 慢性丙型肝炎患者发生重度肝纤维化相关因素分析^*[J]. 实用肝脏病杂志, 2019, 22(2): 196-199.
[12]	谢晓（综述）,陆伦根（审校）. 无创诊断和评估非酒精性脂肪性肝炎研究进展^*[J]. 实用肝脏病杂志, 2019, 22(2): 301-306.
[13]	玉苏甫·吐尔逊, 赵燕霞. 小剂量二乙基亚硝胺诱导大鼠肝纤维化模型的建立[J]. 实用肝脏病杂志, 2019, 22(1): 33-36.
[14]	郭晓霞, 郭琲婷, 孔祥璐. 脾切除对原发性胆汁性肝硬化小鼠肝组织纤维化影响研究^*[J]. 实用肝脏病杂志, 2018, 21(6): 837-841.
[15]	刘恩强, 陈果, 廖修用, 许美凤, 魏贵玉, 罗小平. 虾青素对肝纤维化大鼠的保护作用及机制研究^*[J]. 实用肝脏病杂志, 2018, 21(6): 842-846.